1
|
Bethlen S, Bornheim S, Delvaux F, Marquet L, Pelzer D, Neuprez A, Lecart MP, Maertens B, Wang FC, Tomasella M, Croisier JL, Servais D, Gobels C, Kaux JF. [Innovations in physical and rehabilitation medicine]. Rev Med Liege 2020; 75:445-451. [PMID: 32496695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Over the last decade, Physical and Rehabilitation Medicine (PRM) is a medical specialty that has evolved considerably in the various fields that concern it : from the management of low back pain and lumbosciatalgia or osteoporosis in a multidisciplinary manner, through the use of new technologies in neuro-locomotor rehabilitation and robotisation in amputee patients for example, the development of regenerative medicine and prevention in sports traumatology and, finally, the progress of electrophysiology techniques for the diagnosis of small-fibre neuropathies. These various advances will be discussed in this article.
Collapse
Affiliation(s)
- S Bethlen
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
| | - S Bornheim
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
| | - F Delvaux
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
| | - L Marquet
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
| | - D Pelzer
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
| | - A Neuprez
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
- Service Pluridisciplinaire de Médecine et Traumatologie du Sport (SportS2), Centre Médical d'Excellence de la FIFA, Centre de Recherche du CIO, Centre de Médecine du Sport de la FIMS, CHU Liège, Belgique
| | - M P Lecart
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
| | - B Maertens
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
| | - F C Wang
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
| | - M Tomasella
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
- Service Pluridisciplinaire de Médecine et Traumatologie du Sport (SportS2), Centre Médical d'Excellence de la FIFA, Centre de Recherche du CIO, Centre de Médecine du Sport de la FIMS, CHU Liège, Belgique
- Département des Sciences de la Motricité, Université de Liège, Belgique
| | - J L Croisier
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
- Service Pluridisciplinaire de Médecine et Traumatologie du Sport (SportS2), Centre Médical d'Excellence de la FIFA, Centre de Recherche du CIO, Centre de Médecine du Sport de la FIMS, CHU Liège, Belgique
- Département des Sciences de la Motricité, Université de Liège, Belgique
| | - D Servais
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
| | - C Gobels
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
| | - J F Kaux
- Service de Médecine Physique, Réadaptation et Traumatologie du Sport, CHU Liège, Belgique
- Service Pluridisciplinaire de Médecine et Traumatologie du Sport (SportS2), Centre Médical d'Excellence de la FIFA, Centre de Recherche du CIO, Centre de Médecine du Sport de la FIMS, CHU Liège, Belgique
- Département des Sciences de la Motricité, Université de Liège, Belgique
| |
Collapse
|
2
|
Neuprez A, Bruyère O, Dardenne N, Distèche S, Maheu E, Burlet N, D'Hooghe P, Reginster JY. Assessment and determinants of aesthetic discomfort in hand osteoarthritis. Ann Rheum Dis 2015; 74:1942. [PMID: 26242442 PMCID: PMC4602269 DOI: 10.1136/annrheumdis-2015-207718] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Accepted: 07/14/2015] [Indexed: 11/23/2022]
Affiliation(s)
- A Neuprez
- Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
| | - O Bruyère
- Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
| | - N Dardenne
- Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
| | - S Distèche
- Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
| | - E Maheu
- Department of Rheumatology, AP-HP, St. Antoine Hospital, Paris, France
| | - N Burlet
- Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
| | - P D'Hooghe
- Department of Orthopaedics and Sports Medicine, Aspetar Hospital, Doha, Qatar
| | - J Y Reginster
- Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
| |
Collapse
|
3
|
Neuprez A, Bruyère O, Dardenne N, Disteche S, Maheu E, Burlet N, Reginster JY. OP0110 Assessment and Determinants of Aesthetic Discomfort in Hand Osteoarthritis: The Liège Hand Osteoarthritis Cohort (LIHOC). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
4
|
Neuprez A, Bruyère O, Dardenne N, Distèche S, Maheu E, Burlet N, Reginster JY. AB1230-HPR Baseline Characteristics of the Liège Hand Osteoarthritis Cohort (LIHOC). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
5
|
Reginster JY, Neuprez A, Lecart MP, Beaudart C, Buckinx F, Slomian J, Bruyère O. [OSTEOPOROSIS AND PERSONALIZED MEDICINE]. Rev Med Liege 2015; 70:321-324. [PMID: 26285460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Osteoporosis is at the very early stages of the implementation of personalized medicine. However, the development of FRAX®, an algorithm offering the opportunity to calculate, in an individual patient, his/her 10-year fracture risk improves the decision process on the appropriateness to initiate a pharmacological treatment. This algorithm helps the physician to select drugs which are active on non-vertebral fractures only in high risk patients. Taking into consideration patients' preferences, when selecting a therapeutic option, will improve long term adherence and subsequently efficacy and efficiency of the treatments. Attempts to define the natural course of osteoporosis or the response to therapy in individual patients by assessing their genetic profile remains, so far, inconclusive.
Collapse
|
6
|
Abstract
During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally at all skeletal sites (i.e. spine, hip, and other non-spine). The armamentarium against osteoporosis includes anti-resorptive agents (i.e. bisphosphonates, selective estrogen receptor modulators and denosumab), bone-forming agents (i.e. peptides from the parathyroid hormone family) and one agent with a dual mechanism of action (i.e. strontium ranelate). All these medications combine antifracture efficacy with a reasonable benefit/risk profile. However, the choice of a particular chemical entity, in one individual patient is based on the knowledge and expertise of the physician. Prioritization of drugs should be based on the individual profile of the patient, the severity of osteoporosis and the specific contraindications, warnings and precautions of use of the various available medications.
Collapse
Affiliation(s)
- J Y Reginster
- Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, University of Liège, Avenue de l'Hôpital, 1, B23 Sart Tilman, 4020 Liège, Belgium; Bone and Cartilage Metabolism Unit, CHU Centre Ville, University of Liège, Liège, Belgium.
| | - A Neuprez
- Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, University of Liège, Avenue de l'Hôpital, 1, B23 Sart Tilman, 4020 Liège, Belgium; Bone and Cartilage Metabolism Unit, CHU Centre Ville, University of Liège, Liège, Belgium.
| | - N Dardenne
- Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, University of Liège, Avenue de l'Hôpital, 1, B23 Sart Tilman, 4020 Liège, Belgium; Bone and Cartilage Metabolism Unit, CHU Centre Ville, University of Liège, Liège, Belgium.
| | - C Beaudart
- Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, University of Liège, Avenue de l'Hôpital, 1, B23 Sart Tilman, 4020 Liège, Belgium; Bone and Cartilage Metabolism Unit, CHU Centre Ville, University of Liège, Liège, Belgium.
| | - P Emonts
- Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, University of Liège, Avenue de l'Hôpital, 1, B23 Sart Tilman, 4020 Liège, Belgium
| | - O Bruyere
- Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, University of Liège, Avenue de l'Hôpital, 1, B23 Sart Tilman, 4020 Liège, Belgium; Bone and Cartilage Metabolism Unit, CHU Centre Ville, University of Liège, Liège, Belgium.
| |
Collapse
|
7
|
Reginster JY, Neuprez A, Lecart MP, Sarlet N, Distèche S, Bruyère O. [Treatment of post-menopausic osteoporosis: what's new in 2014?]. Rev Med Liege 2014; 69:441-453. [PMID: 25158386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Management of osteoporosis involves both non pharmacological approaches, including changes in lifestyle and dietary habits combined, in patients at high risk of fracture or presenting with an established osteoporosis, to the use of drugs. Besides supplementation in calcium and vitamin D (at daily doses of 1 gr and 800 IU) in patients whose dietary intakes do not cover the recommended daily allowances, medications to be used for the management of osteoporosis may include inhibitors of bone resorption (bisphosphonates, denosumab and selective estrogen receptor modulators), stimulators of bone formation (teriparatide) or chemical entities decreasing bone resorption and stimulating bone formation (strontium ranelate). The selection of a particular medication, for a single individual patient, will depend on the severity of the disease as well as on the patient's believes and expectations. Local, skeletal and systemic tolerance of the various drugs should also be taken into account.
Collapse
|
8
|
Reginster JY, Neuprez A, Beaudart C, Buckinx F, Slomian J, Disteche S, Bruyere O. Bone forming agents for the management of osteoporosis. Panminerva Med 2014; 56:97-114. [PMID: 24642527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Osteoporotic fractures are a major cause of morbidity in the population. Antiresorptive agents have been, for more than 15 years, the mainstay of osteoporosis treatment worldwide. However, these medications provide only limited fracture reduction and may be linked to skeletal and non-skeletal long-term safety concerns. Therefore, some patients are considered candidates for bone-forming agents because they remain severely osteoporotic or because they failed antiresorptive therapy. Over the last decade, a particular interest was shown in the development of medications able to increase osteoblasts number, lifespan or activity, hence stimulating bone formation Peptides from the parathyroid hormone family and strontium ranelate were shown to significantly reduce fracture rates. The European Medicines Agency recently confirmed that strontium ranelate is the treatment of choice for patients with severe osteoporosis, men and women, without cardiovascular contra-indications for whom other anti-osteoporosis medications are inappropriate. New therapeutic options, including monoclonal antibodies against sclerostin seem to be promising but their role in the armamentarium of osteoporosis will depend on the results of the current phase 3 studies, assessing anti-fracture efficacy and long-term safety.
Collapse
Affiliation(s)
- J Y Reginster
- Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, University of Liège, Liège, Belgium -
| | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the receptor activator of nuclear factor kappa-B ligand. It prevents osteoclast-mediated bone resorption and is widely prescribed for the management of postmenopausal osteoporosis. Whereas ONJ has already been reported in women treated with DMab, we report for the first time the development of ONJ, following tooth extraction, in a male patient treated for idiopathic osteoporosis with DMab. Due to the constant increase in DMab prescription, for the management of osteoporosis, in both genders, physicians should be made aware of this potential risk.
Collapse
Affiliation(s)
- A. Neuprez
- Public Health, Epidemiology and Health Economics Department, University of Liège, Belgium, Liège, Belgium
- Bone and Cartilage Metabolism Unit, CHU, Liège, Belgium
- Motricity Sciences Department, CHU, Liège, Belgium
| | - S. Coste
- Gynecology Department, CHC St. Joseph, Liège, Belgium
| | - E. Rompen
- Stomatology Department, CHU, Liège, Belgium
| | | | - J. Y. Reginster
- Public Health, Epidemiology and Health Economics Department, University of Liège, Belgium, Liège, Belgium
- Bone and Cartilage Metabolism Unit, CHU, Liège, Belgium
- Motricity Sciences Department, CHU, Liège, Belgium
- Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, Boulevard de l’Hôpital, 3 4000 Liège, Belgium
| |
Collapse
|
10
|
Neuprez A, François G, Bruyère O, Kovats V, Kurth W, Huskin JP, Gillet P, Reginster JY. AB0959 Radiological and clinical profil of osteoarthritic patients undergoing total joint replacement. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
11
|
Neuprez A, François G, Bruyère O, Kovats V, Thirion T, Van Cauwenberge H, Daniel C, Gillet P, Reginster JY. AB0958 Assessment of quality of life in patients undergoing total joint replacement for OA of the lower limb. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
12
|
Bruyère O, Ethgen O, Neuprez A, Zégels B, Gillet P, Huskin JP, Reginster JY. Health-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study. Arch Orthop Trauma Surg 2012; 132:1583-7. [PMID: 22842917 DOI: 10.1007/s00402-012-1583-7] [Citation(s) in RCA: 77] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2011] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To assess health-related quality of life (HRQOL) in a prospective study with 7 years of follow-up in 49 consecutive patients who underwent a total joint replacement because of osteoarthritis. METHODS Generic HRQOL was assessed with the short-form 36 (SF-36) and specific HRQOL with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). RESULTS Out of the 39 subjects who have completed the 7 years of follow-up of this study, 22 (56.4 %) underwent a hip replacement surgery and the other 17 (43.6 %) a knee replacement. Six months after surgery, a significant improvement, compared to preoperative scores, was observed in two of the eight dimensions of the SF-36 (i.e. physical function and pain). The same dimensions, pain and physical function, at the same time, 6 months after surgery, measured by the WOMAC, showed a significant improvement as well, but there was no significant change in the stiffness score. From 6 months to the end of follow-up, changes in SF-36 scores showed a significant improvement in physical function (p = 0.008), role-physical (p = 0.004) and role-emotional (p = 0.01) while all scores of the WOMAC improved (p < 0.001 for pain, p < 0.001 for stiffness and p < 0.01 for physical function). CONCLUSION The improvements observed in HRQOL at short term after surgery, are at least maintained over a 7-year follow-up period.
Collapse
Affiliation(s)
- O Bruyère
- Department of Epidemiology, Public Health and Health Economics, University of Liège, CHU Sart-Tilman, Bât B23, 4000, Liège, Belgium.
| | | | | | | | | | | | | |
Collapse
|
13
|
Bruyère O, Fossi M, Zegels B, Leonori L, Hiligsmann M, Neuprez A, Reginster JY. Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatol Int 2012; 33:973-8. [PMID: 22842952 DOI: 10.1007/s00296-012-2460-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2012] [Accepted: 07/07/2012] [Indexed: 11/30/2022]
Abstract
To assess the number of anti-osteoporosis treatments that would be reimbursed by the Belgian social security if either FRAX or the current criteria were used to determine access to reimbursement. This is a retrospective study based on data from 1,000 women randomly selected from an outpatient hospital specialized in bone metabolism in Belgium. Proportions of potentially refunded treatments between FRAX and current criteria were compared. Out of the 1,000 women files, 890 have sufficient information to assess FRAX. In Belgium, current criteria include a bone mineral density (BMD) T score below -2.5 at the lumbar spine, the femoral neck or the total hip and/or at least a prevalent vertebral fracture. Using these criteria, 167 women (18.8 %) would have access to reimbursement. Using the criteria based on the validated Belgian FRAX tool, only 116 women (13.0 %) would have access to reimbursement, meaning that access to reimbursement based on FRAX criteria would reduce by 30 % the anti-osteoporosis drug expenses covered by the national social security. Interestingly, only 65 women out of the 116 (56.0 %) selected with the FRAX criteria were also selected with the current criteria of the national social security. A substantial proportion of individuals that would potentially receive a reimbursement for their treatment using the FRAX criteria do not have access to any refund for their treatment with the current criteria. Since patients identified with the FRAX tool are those with the highest risk profile for future fractures, reappraisals of treatment reimbursement guidelines are expected in Belgium.
Collapse
Affiliation(s)
- O Bruyère
- Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Bât B23 Av. de l'Hôpital 3, 4000 Liège, Belgium.
| | | | | | | | | | | | | |
Collapse
|
14
|
Johansson H, Kanis JA, McCloskey EV, Odén A, Devogelaer JP, Kaufman JM, Neuprez A, Hiligsmann M, Bruyere O, Reginster JY. A FRAX® model for the assessment of fracture probability in Belgium. Osteoporos Int 2011; 22:453-61. [PMID: 20352409 DOI: 10.1007/s00198-010-1218-1] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2009] [Accepted: 01/26/2010] [Indexed: 01/07/2023]
Abstract
UNLABELLED A country-specific FRAX® model was developed from the epidemiology of fracture and death in Belgium. Fracture probabilities were identified that corresponded to currently accepted reimbursement thresholds. INTRODUCTION The objective of this study was to evaluate a Belgian version of the WHO fracture risk assessment (FRAX®) tool to compute 10-year probabilities of osteoporotic fracture in men and women. A particular aim was to determine fracture probabilities that corresponded to the reimbursement policy for the management of osteoporosis in Belgium and the clinical scenarios that gave equivalent fracture probabilities. METHODS Fracture probabilities were computed from published data on the fracture and death hazards in Belgium. Probabilities took account of age, sex, the presence of clinical risk factors and femoral neck bone mineral density (BMD). Fracture probabilities were determined that were equivalent to intervention (reimbursement) thresholds currently used in Belgium. RESULTS Fracture probability increased with age, lower BMI, decreasing BMD T-score and all clinical risk factors used alone or combined. The 10-year probabilities of a major osteoporosis-related fracture that corresponded to current reimbursement guidelines ranged from approximately 7.5% at the age of 50 years to 26% at the age of 80 years where a prior fragility fracture was used as an intervention threshold. For women at the threshold of osteoporosis (femoral neck T-score = -2.5 SD), the respective probabilities ranged from 7.4% to 15%. Several combinations of risk-factor profiles were identified that gave similar or higher fracture probabilities than those currently accepted for reimbursement in Belgium. CONCLUSIONS The FRAX® tool has been used to identify possible thresholds for therapeutic intervention in Belgium, based on equivalence of risk with current guidelines. The FRAX® model supports a shift from the current DXA-based intervention strategy, towards a strategy based on fracture probability of a major osteoporotic fracture that in turn may improve identification of patients at increased fracture risk. The approach will need to be supported by health economic analyses.
Collapse
Affiliation(s)
- H Johansson
- WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Scholtissen S, Bruyère O, Neuprez A, Severens JL, Herrero-Beaumont G, Rovati L, Hiligsmann M, Reginster JY. Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract 2010; 64:756-62. [PMID: 20518951 DOI: 10.1111/j.1742-1241.2010.02362.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
INTRODUCTION The aim of this study was to explore the cost-effectiveness of glucosamine sulphate (GS) compared with paracetamol and placebo (PBO) in the treatment of knee osteoarthritis. For this purpose, a 6-month time horizon and a health care perspective was used. MATERIAL AND METHODS The cost and effectiveness data were derived from Western Ontario and McMaster Universities Osteoarthritis Index data of the Glucosamine Unum In Die (once-a-day) Efficacy trial study by Herrero-Beaumont et al. Clinical effectiveness was converted into utility scores to allow for the computation of cost per quality-adjusted life year (QALY) For the three treatment arms Incremental Cost-Effectiveness Ratio were calculated and statistical uncertainty was explored using a bootstrap simulation. RESULTS In terms of mean utility score at baseline, 3 and 6 months, no statistically significant difference was observed between the three groups. When considering the mean utility score changes from baseline to 3 and 6 months, no difference was observed in the first case but there was a statistically significant difference from baseline to 6 months with a p-value of 0.047. When comparing GS with paracetamol, the mean baseline incremental cost-effectiveness ratio (ICER) was dominant and the mean ICER after bootstrapping was -1376 euro/QALY indicating dominance (with 79% probability). When comparing GS with PBO, the mean baseline and after bootstrapping ICER were 3617.47 and 4285 euro/QALY, respectively. CONCLUSION The results of the present cost-effectiveness analysis suggested that GS is a highly cost-effective therapy alternative compared with paracetamol and PBO to treat patients diagnosed with primary knee OA.
Collapse
Affiliation(s)
- S Scholtissen
- Department of Public Health, University of Liege, Liege, Belgium
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Neuprez A, Johansson H, Kanis JA, McCloskey EV, Odén A, Bruyère O, Hiligsmann M, Devogelaer JP, Kaufman JM, Reginster JY. [A FRAX model for the assessment of fracture probability in Belgium]. Rev Med Liege 2009; 64:612-619. [PMID: 20143744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The objective of this study was to evaluate a Belgian version of the WHO fracture risk assessment (FRAX) tool to compute 10-year probabilities of osteoporotic fracture in men and women. A particular aim was to determine fracture probabilities that corresponded to the reimbursement policy for the management of osteoporosis in Belgium and the clinical scenarios that gave equivalent fracture probabilities. Fracture probabilities were computed from published data on the fracture and death hazards in Belgium. Probabilities took account of age, sex, the presence of clinical risk factors and femoral neck BMD. Fracture probabilities were determined that were equivalent to intervention (reimbursement) thresholds currently used in Belgium. Fracture probability increased with age, lower BMI, decreasing BMD T-Score, and all clinical risk factors used alone or combined. The FRAX tool has been used to identify possible thresholds for therapeutic intervention in Belgium, based on equivalence of risk with current guidelines. The FRAX model supports a shift from the current DXA based intervention strategy, towards a strategy based on fracture probability of a major osteoporotic fracture that in turn may improve identification of patients at increased fracture risk. The approach will need to be supported by health economic analyses.
Collapse
Affiliation(s)
- A Neuprez
- Département des Sciences de la Santé Publique, Service de Santé Publique, Epidémiologie et Economie de la Santé, Faculté de Médecine, Université de Liège.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Neuprez A, Hiligsmann M, Bruyère O, Reginster JY. [Anti-fracture efficacy of intravenous ibandronate: how to translate epidemiological studies into daily clinical practice]. Rev Med Liege 2009; 64:525-529. [PMID: 19911667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Numerous epidemiological approaches are used to demonstrate the efficacy of a new chemical entity. In postmenopausal osteoporosis, anti-fracture efficacy can be assessed through prospective, randomized controlled trials, meta-analyses or real-life setting studies. Intravenous ibandronate was recently marketed, with the aim of optimizing drug absorption and adherence to treatment. Furthermore, this new formulation avoids gastrointestinal side effects and constrains linked to the oral intake of the medication. Spinal anti-fracture efficacy of IV ibandronate derives from a non-inferiority bridging study, using surrogate endpoints, i.e., bone mineral density and biochemical markers of bone turnover, compared to the oral daily formulation, previously registered for the treatment of osteoporosis in Europe. Coherent results from two separate meta-analyses have suggested that the non-vertebral anti-fracture efficacy of IV ibandronate is similar to that observed with oral, daily and weekly bisphosphonates. Similarly, a recent real-life setting study, based on claims from an US database, suggests that hip fractures are reduced, with IV ibandronate, to the same extend as they are with oral bisphosphonates. Notwithstanding, those results should probably be confirmed in an European setting, before being extrapolated, in daily practice, to the Belgian population.
Collapse
Affiliation(s)
- A Neuprez
- Département des Sciences de la Santé Publique, Service de Santé Publique, Epidémiologie et Economie de la Santé, Faculté de Médecine, Université de Liège
| | | | | | | |
Collapse
|
18
|
Bruyère O, Scholtissen S, Neuprez A, Hiligsmann M, Toukouki A, Reginster JY. Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. J Med Econ 2009; 12:356-60. [PMID: 19900070 DOI: 10.3111/13696990903438617] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVES The first objective was to assess the effect of the chondroitin 4 and 6 sulphate (CS) on health-related quality of life using utility values in patients with knee osteoarthritis (OA) during a 24-month treatment course. The second objective was, using these data, to conduct economic analyses. METHODS Data from the STOPP study was used. This study was a randomised, double-blind, placebo (PL) -controlled trial of 2-year duration. In the STOPP study, authors assessed quality of life using the Western Ontario and McMaster Osteoarthritis Index (WOMAC). WOMAC scores were translated into Health Utility Index (HUI) scores using a specific formula. Incremental cost effectiveness ratio (ICER) was calculated taking into account the cost of CS and its effect on HUI scores, compared to PL. RESULTS At baseline, the mean (SD) HUI scores were 0.59 (0.17), and 0.59 (0.18) for the PL and CS groups, respectively (p=0.31 between the two groups). The mean (SD) HUI scores changes from baseline to 6 months were 0.02 (0.02), and 0.05 (0.01) for the PL and CS groups, respectively (p=0.03). After 24 months of follow-up, HUI score increases by 0.04 (0.02) in the PL group and by 0.05 (0.02) in the CS group (p=0.37). Using the price bracket of CS in Europe, ICER assessment always resulted in a cost below €30,000 per QALY gained, after 6, 12 and 24 months of treatment. CONCLUSION CS treatment increases health utilities in patients with knee OA compared to PL over the first 6 months of treatment. Economic evaluation based on these data suggests that CS treatment could be considered as cost-effective in patients with knee OA up to a period of 24 months. A limitation in this study is the absence of direct utility assessment as well as the absence of effective treatment as comparator.
Collapse
Affiliation(s)
- O Bruyère
- Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium.
| | | | | | | | | | | |
Collapse
|
19
|
Malaise O, Neuprez A, Reginster JY. Traitements non hormonaux de l’ostéoporose postménopausique. ACTA ACUST UNITED AC 2008; 36:815-22. [DOI: 10.1016/j.gyobfe.2007.05.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2008] [Accepted: 05/28/2008] [Indexed: 10/21/2022]
|
20
|
Abstract
OBJECTIVES To evaluate the interest of using the various preparations of glucosamine for symptomatic and structural management of osteoarthritis (OA). METHODS A critical analysis of the literature based on an exhaustive search (Medline, PubMed and manual search within the bibliography of retrieved manuscripts) from 1980 to 2005. RESULTS Despite multiple controlled clinical trials of the use of glucosamine in OA (mainly of the knee), controversy on efficacy related to symptomatic improvement continues. Differences in results originate from the differences in products, study design and study populations. Symptomatic efficacy described in multiple studies performed with glucosamine sulphate (GS) support continued consideration in the OA therapeutic armamentarium. The most compelling evidence of a potential for inhibiting the progression of OA is also obtain with GS. CONCLUSIONS GS has shown positive effects on symptomatic and structural outcomes of knee OA. These results should not be extrapolated to other glucosamine salts [hydrochloride or preparations (over-the-counter or food supplements)] in which no warranty exists about content, pharmacokinetics and pharmacodynamics of the tablets.
Collapse
Affiliation(s)
- J-Y Reginster
- WHO Collaborating Center, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
| | | | | |
Collapse
|
21
|
Abstract
Osteoporosis results from a decrease in bone strength yielding increased susceptibility to fractures. Hip and spine fractures are a major cause of morbidity and mortality in the elderly population. With an increasingly ageing world population, early prevention of bone loss is essential for adequate control of this condition. Strontium ranelate (PROTELOS((R))), an oral drug for postmenopausal osteoporosis, has been reported to decrease bone resorption and to stimulate bone formation. The efficacy in reducing vertebral fractures, non-vertebral including hip fractures, and the safety of strontium ranelate has been initially demonstrated over 3 years in the SOTI (Spinal Osteoporosis Therapeutic Intervention) and TROPOS (TReatment Of Peripheral OSteoporosis) studies and confirmed recently over up to 5 years. A preplanned analysis of a sub-group of patients aged 80 years and over showed that, currently, strontium ranelate is the only antiosteoporotic agent to reduce vertebral and non-vertebral fractures in this age group.
Collapse
Affiliation(s)
- J-Y Reginster
- Bone and Cartilage Metabolism Unit, University of Liège, Liège, Belgium.
| | | | | | | |
Collapse
|
22
|
Bruyère O, Malaise O, Neuprez A, Collette J, Reginster JY. Prévalence élevée de la carence en vitamine D chez la femme ménopausée en Europe et principalement en France: analyse d'une cohorte de 8532 sujets. ACTA ACUST UNITED AC 2006. [DOI: 10.1016/j.rhum.2006.10.070] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Neuprez A, Gillet P, Collette C, Reginster JY. [Bone densitometry for the diagnosis of osteoporosis: the Belgian reimbursement paradox]. Rev Med Liege 2006; 61:249-55. [PMID: 16789613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Osteoporosis is considered as a major Public Health issue, in most developed countries. Bone mineral density assessment is the single best predictor of the future fracture risk for an individual. Belgium has the highest number of bone densitometers, per million habitants, in Europe. However, densitometry is not yet reimbursed in Belgium. This situation is rather paradoxical since the demonstration of a prevalent vertebral fracture or of a low bone mineral density is requested to obtain the reimbursement of drugs to be used for the management of osteoporosis. Hopefully, Belgium will soon be online with the requirement s of the European Commission, suggesting to make bone densitometry accessible, through reimbursement.
Collapse
Affiliation(s)
- A Neuprez
- Service de la Santé Publique, Epidémiologie et Economie de la Santé, CHU Sart Tilman, Université de Liège
| | | | | | | |
Collapse
|
24
|
Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006; 38:S2-6. [PMID: 16520104 DOI: 10.1016/j.bone.2006.01.150] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2005] [Revised: 11/02/2005] [Accepted: 01/26/2006] [Indexed: 10/24/2022]
Abstract
Adherence to treatment among patients with chronic diseases is currently suboptimal. Poor adherence leads to reduced clinical benefit, a raised incidence of secondary complications and therefore increased healthcare costs. For patients with osteoporosis, long-term adherence to therapy is further complicated by the asymptomatic nature of the disease and the lack of options for patient self-monitoring. Bone densitometry and biochemical markers of bone turnover are assessments that could be used by physicians to provide feedback to patients on the effectiveness of medication. However, these feedback systems are costly and not readily available. Oral bisphosphonates are currently the first-line therapy for postmenopausal osteoporosis. However, they are associated with stringent dosing procedures, and some patients may experience upper gastrointestinal side-effects following administration. Alarmingly, approximately 50% of patients discontinue daily bisphosphonate therapy within 1 year, which negatively impacts upon treatment outcomes, leading to a reduced antifracture effect. Thus, there is a need for an effective therapy that enhances patient adherence. The impact of reducing bisphosphonate dosing frequency on therapeutic adherence has been documented in several studies. Data have shown that, although weekly dosing improves adherence compared with daily administration, levels are still suboptimal. Results from two recent studies that have assessed patient preference for a once-monthly compared with a weekly dosing schedule have demonstrated that patients prefer a monthly regimen (67-71%). Their reasons for preferring once-monthly dosing were that it would fit better with their lifestyle (49-77%) and would be more convenient (75%). A novel once-monthly bisphosphonate regimen, such as the ibandronate regimen, may therefore help patients to follow dosing guidelines and encourage them to stay on therapy longer, thereby improving overall therapy effectiveness.
Collapse
Affiliation(s)
- J Y Reginster
- WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases, University of Liège, Liège, Belgium.
| | | | | |
Collapse
|
25
|
Neuprez A, Haykal S, Calteux N. [The use of an inferior dermo-glandular flap in Thorek's technique, based on a series of 21 cases]. ANN CHIR PLAST ESTH 1999; 44:231-7. [PMID: 10427830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
Thorek's technique, first described in 1922 for breast reductions, has been progressively replaced by techniques using a dermoglandular pedicle. This first technique is still performed today in cases of major hypertrophy. But the major disadvantage is the tendency for the breast to be too flat post-reduction. We tried to correct this problem by preserving an inferior dermoglandular flap rolled into a cone shape before positioning it within the bulk of the breast, thus giving a better projection. The authors present a series of 21 patients operated by this technique with a median follow-up of two years. The preliminary results are encouraging and we think that this procedure is a treatment of choice in cases of gigantomastia.
Collapse
Affiliation(s)
- A Neuprez
- Service de Chirurgie Plastique Reconstructrice et Esthétique et Chirurgie de la Main, Centre Hospitalier du Luxembourg
| | | | | |
Collapse
|